• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:王峰,贾飞,高素英,李会林.LC-MS/MS测定人血浆中罗红霉素的浓度及其在生物等效性研究中的应用[J].中国现代应用药学,2012,29(12):1128-1131.
WANG Feng,JIA Fei,GAO Suying,LI Huilin.Determination of Roxithromycin in Plasma by LC-MS/MS and Its Application in the Bioequivalence Study[J].Chin J Mod Appl Pharm(中国现代应用药学),2012,29(12):1128-1131.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2345次   下载 2021 本文二维码信息
码上扫一扫!
分享到: 微信 更多
LC-MS/MS测定人血浆中罗红霉素的浓度及其在生物等效性研究中的应用
王峰, 贾飞, 高素英, 李会林
浙江省食品药品检验研究院,杭州 310004
摘要:
目的 建立LC-MS/MS测定人血浆中罗红霉素浓度的方法,并研究其制剂的生物等效性。方法 以克拉霉素为内标,色谱柱:Alltech Alltima(2.1 mm×100 mm,3.5 μm);流动相:0.1%甲酸溶液-乙腈(45∶55);流速:0.2 mL·min-1;柱温:30 ℃。采用三重四极杆串联质谱,电喷雾离子源,正离子模式检测,以选择反应监测(SRM)方式进行检测,罗红霉素母离子[M+H]+m/z 837.5,子离子m/z 679.2,内标克拉霉素母离子[M+H]+m/z 748.5,子离子m/z 590.2。结果 罗红霉素线性范围为0.10~20.00 μg·mL-1,最低检测限为0. 01 μg·mL-1,3种浓度的相对回收率为100.8%~103.1%,日内、日间RSD均<5.9%(n=5)。生物等效性研究表明受试制剂和参比制剂生物等效,受试制剂相对生物利用度为(100.655±9.552)% (P=0.5%)。结论 该方法专属、灵敏、快速,适用于罗红霉素制剂的生物等效性研究。
关键词:  罗红霉素  液相色谱-串联质谱法  生物等效性
DOI:
分类号:
基金项目:
Determination of Roxithromycin in Plasma by LC-MS/MS and Its Application in the Bioequivalence Study
WANG Feng, JIA Fei, GAO Suying, LI Huilin
Zhejiang Institute for Food and Drug Control, Hangzhou 310004, China
Abstract:
OBJECTIVE To establish a LC-MS/MS method for determination of roxithromycin in plasma and to study its bioequivalence. METHODS Clarithromycin was used as internal standard. The method was performed on Alltech Alltima (2.1 mm×100 mm, 3.5 μm) at 30 ℃, and 0.1% formic acid-acetonitrile(45∶55) was used as mobile phase with the flow rate of 0.2 mL·min-1. Electrospray ionization source was applied and operated in positive ion mode. Selected reaction monitoring(SRM) mode with the transitions of m/z 837.5→679.2 and m/z 748.5→590.2 was used to quantify roxithromycin and clarithromycin, respectively. RESULTS The assay was linear over the range of 0.10-20.00 μg·mL-1, the limit of detection was 0.01 μg·mL-1, relative recoveries at three level concentrations ranged from 100.8% to 103.1%, the intra- and inter-day precision(RSD) were below 5.9%. Bioequivalence study showed the test roxithromycin tablets was bioequivalent to the reference tablets. The relative bioavail-ability of the test sample was (100.655±9.552)%(P=0.5%). CONCLUSION The method is simple, rapid, accurate and can be applied to perform the bioequivalence research of roxithromycin tablets.
Key words:  roxithromycin  LC-MS/MS  bioequivalence
扫一扫关注本刊微信